Innoviva, Inc.
For the period ended Dec 31, 2025. Filed Feb 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 25, 2026
INVA$19.00-0.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Exhibits
| Incorporated by Reference · Filed Herewith | ||||
|---|---|---|---|---|
| ExhibitNumber | Description | Form | Exhibit | FilingDate/PeriodEnd Date |
| 2.1 | Agreement and Plan of Merger, dated as of May 23, 2022, by and among Innoviva, Inc., Innoviva Merger Sub, Inc. and Entasis Therapeutics | 8-K | 2.1 | 5/24/2022 |
| 2.2 | Agreement and Plan of Merger, dated as of July 10, 2022, by and among Innoviva, Inc., Innoviva Acquisition Sub, Inc. and La Jolla Pharmaceutical Company | 8-K | 2.1 | 7/11/2022 |
| 3.1 | Amended and Restated Certificate of Incorporation | 8‑K | 99.2 | 4/28/2016 |
| 3.2 | Amended and Restated Bylaws, amended and restated as of January 1, 2023 | 8‑K | 3.1 | 1/4/2023 |
| 4.1 | Specimen certificate representing the common stock of the registrant | 10‑K | 4.1 | 12/31/2006 |
| 4.2 | Indenture, dated as of January 24, 2013 by and between Theravance, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee | 8‑K | 4.1 | 1/25/2013 |
| 4.3 | Form of 2.125% Convertible Subordinated Note Due 2023 | 8-K | 4.1 | 1/25/2013 |
| 4.4 | Indenture (including form of Note) with respect to Innoviva’s 2.50% Convertible Senior Notes due 2025, dated as of August 7, 2017, between Innoviva and The Bank of New York Mellon Trust Company, N.A., as trustee | 8‑K | 4.1 | 8/7/2017 |
| 4.5 | Description of Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 | 10-K | 4.9 | 2/19/2020 |
| 4.6 | Indenture (including form of Note) with respect to Innoviva’s 2.125% Convertible Senior Notes due 2028, dated as of March 7, 2022, between Innoviva, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee | 8-K | 4.1 | 3/8/2022 |
| 10.2 | Collaboration Agreement between the registrant and Glaxo Group Limited, dated as of November 14, 2002 | 10‑Q | 10.1 | 6/30/2014 |
| 10.3 | Amended and Restated Investors’ Rights Agreement by and among the registrant and the parties listed therein, dated as of May 11, 2004 | S‑1 | 10.13 | 6/10/2004 |
| 10.4* | Strategic Alliance Agreement between the registrant and Glaxo Group Limited, dated as of March 30, 2004 | 10‑K | 10.13 | 12/31/2013 |
| 10.5+ | Description of Cash Bonus Program, as amended | 10‑K | 10.22 | 12/31/2009 |
| 10.6+ | Amendment to Change in Control Severance Plan effective December 16, 2009 | 10‑K | 10.47 | 12/31/2009 |
| 10.7+ | 2009 Change in Control Severance Plan adopted December 16, 2009 | 10‑K | 10.48 | 12/31/2009 |
| 10.8 | Second Amendment to Amended and Restated Governance Agreement among the registrant, Glaxo Group Limited, GlaxoSmithKline plc and GlaxoSmithKline LLC, dated as of November 29, 2010 | 8‑K | 10.2 | 11/29/2010 |
| 10.9 | Amendment to Strategic Alliance Agreement, dated October 3, 2011 | 10‑K | 10.34 | 12/31/2011 |
| 10.10+ | 2012 Equity Incentive Plan, as approved by the board of directors February 8, 2012 and approved by stockholders May 16, 2012 and forms of equity award | 10‑Q | 10.38 | 6/30/2012 |
| 10.11 | Base Capped Call Transaction, dated January 17, 2013 | 8‑K | 10.1 | 1/23/2013 |
| 10.12 | Additional Capped Call Transaction, dated January 18, 2013 | 8‑K | 10.2 | 1/23/2013 |
| 10.13 | Master Agreement by and among Theravance, Inc., Theravance Biopharma, Inc. and Glaxo Group Limited, dated March 3, 2014 | 8‑K/A | 10.1 | 3/6/2014 |
| 10.14* | Collaboration Agreement Amendment by and between Theravance, Inc. and Glaxo Group Limited, dated March 3, 2014 | 8‑K/A | 10.2 | 3/6/2014 |
| 10.15* | Strategic Alliance Agreement Amendment by and between Theravance, Inc. and Glaxo Group Limited, dated March 3, 2014 | 8‑K/A | 10.3 | 3/6/2014 |
| 10.16 | Transition Services Agreement between Theravance and Theravance Biopharma, dated June 2, 2014 | 8‑K | 10.2 | 6/5/2014 |
| 10.17 | Tax Matters Agreement between Theravance and Theravance Biopharma, dated June 2, 2014 | 8‑K | 10.3 | 6/5/2014 |
| 10.18 | Employee Matters Agreement between Theravance and Theravance Biopharma, dated June 1, 2014 | 8‑K | 10.4 | 6/5/2014 | |
| 10.19 | Theravance Respiratory Company, LLC Limited Liability Company Agreement between Theravance and Theravance Biopharma, dated May 31, 2014 | 8‑K | 10.5 | 6/5/2014 | |
| 10.20 | Amendment/Clarification to Transition Services Agreement between Theravance and Theravance Biopharma, dated March 2, 2015 | 10‑Q | 10.64 | 3/31/2015 | |
| 10.21+ | First Amendment to 2009 Change In Control Severance Plan (Renamed 2009 Severance Plan) | 8‑K | 10.2 | 7/29/2015 | |
| 10.22 | Form of Notice of Performance‑Based Restricted Stock Award and Restricted Stock Award Agreement under 2012 Equity Incentive Plan (director form) | 10‑K | 10.76 | 2/23/2018 | |
| 10.23+ | Second Amendment to 2009 Severance Plan | 10‑Q | 10.81 | 7/26/2018 | |
| 10.24+ | Offer Letter with Marianne Zhen, dated September 7, 2018 | 8‑K | 10.1 | 9/11/2018 | |
| 10.25+ | Offer Letter between Innoviva, Inc. and Pavel Raifeld, dated May 20, 2020 | 8‑K | 10.1 | 5/26/2020 | |
| 10.26+ | Offer Letter between Innoviva, Inc. and Pavel Raifeld, dated April 29, 2022 | 8-K | 10.1 | 5/2/2022 | |
| 10.27 | Strategic Advisory Agreement, dated as of December 11, 2020, by and between Sarissa Capital Management LP and Innoviva, Inc. | 8‑K | 10.1 | 12/14/2020 | |
| 10.28 | Amended and Restated Limited Partnership Agreement of ISP Fund LP, dated as of December 11, 2020, by and among ISP Fund LP, Sarissa Capital Fund GP LP, Innoviva Strategic Partners LLC and the other parties named therein | 8‑K | 10.2 | 12/14/2020 | |
| 10.29 | Share Repurchase Agreement, dated as of May 2021, by and between Innoviva, Inc. and Glaxo Group Limited | 8-K | 10.1 | 5/20/2021 | |
| 10.30 | Letter Agreement, dated as of May 20, 2021, by and among Innoviva Strategic Partners LLC, ISP Fund LP and Sarissa Capital Fung GP LP | 8-K | 10.2 | 5/20/2021 | |
| 10.31 | Capped Call Confirmation dated March 2, 2022, by and among Innoviva, Inc., Bank of America, N.A., Goldman Sachs & Co. LLC and Deutsche Bank AG, London Branch | 8-K | 10.1 | 3/8/2022 | |
| 10.32 | Amendment No. 1 to the Investor Rights Agreement, dated May 23, 2022, by and among Innoviva, Inc. and Entasis Therapeutics Holdings Inc. | 8-K | 10.1 | 5/24/2022 | |
| 10.33 | Support Agreement, dated July 10, 2022, by and among Innoviva, Inc., Innoviva Acquisition Sub, Inc., Tang Capital Partners, LP and Kevin C. Tang Foundation | 8-K | 10.1 | 7/11/2022 | |
| 10.34 | Equity Purchase Agreement, dated July 13, 2022, by and among Innoviva, Inc., Innoviva TRC Holdings LLC and Royalty Pharma Investments 2019 ICAV | 8-K | 10.1 | 7/13/2022 | |
| 10.35 | Third Amendment to Collaboration Agreement, dated July 13, 2022, by and among Innoviva, Inc., Glaxo Group Limited, and Theravance Respiratory Company, LLC. | 8-K | 10.2 | 7/13/2022 | |
| 10.36+ | Transition Agreement between Larry Edwards and Innoviva Specialty Therapeutics, Inc., dated February 23, 2023, and Release of Claims form signed by Larry Edwards, dated April 5, 2023 | 10-Q | 10.1 | 5/9/2023 | |
| 10.37 | 2023 Employee Stock Purchase Plan | DEF 14A | 4/28/2023 | ||
| 10.38+ | Offer Letter between Innoviva, Inc. and Stephen Basso dated July 28, 2023 | 8-K | 10.1 | 8/25/2023 | |
| 19 | Amended and Restated Insider Trading Policy and Guidelines with Respect to Certain Transactions in Securities (effective as of March 15, 2023) | 10-K | 19 | 12/31/2024 | |
| 21.1 | List of Subsidiaries | X | |||
| 23.1 | Consent of Independent Registered Public Accounting Firm | X | |||
| 23.3 | Consent of Ernst & Young LLP Independent Registered Public Accounting Firm of Armata Pharmaceuticals, Inc.** | ||||
| 31.1 · Certification of Principal Executive Officer Pursuant to Rule 13a‑14 under the Securities Exchange Act of 1934 · X | |||||
|---|---|---|---|---|---|
| 31.2 · Certification of Principal Financial Officer Pursuant to Rule 13a‑14 under the Securities Exchange Act of 1934 · X | |||||
| 32# · Certifications Pursuant to 18 U.S.C. Section 1350 | |||||
| 97 | Innoviva Clawback Policy (effective as of October 2, 2023) | 10-K | 97 | 2/29/2024 | |
| 99.1 | Audited Consolidated Financial Statements of Armata Pharmaceuticals, Inc. at December 31, 2025, for the year ended December 31, 2025** | ||||
| 101.INS | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | X | |||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | X | |||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | X | |||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | X | |||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | X | |||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | X | |||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | X | |||
- Management contract or compensatory plan or arrangement required to be filed pursuant to Item 15(b) of Form 10‑K.
- Confidential treatment has been granted for certain portions which are omitted in the copy of the exhibit electronically filed with the Securities and Exchange Commission. The omitted information has been filed separately with the Securities and Exchange Commission pursuant to Innoviva, Inc.’s application for confidential treatment.
** To be filed by amendment to this Annual Report on Form 10-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.